By quantifying tissue remodeling, our biomarkers provide true prognostic and predictive value, as we can select the patients who are most likely to respond to a given treatment and thereby function as surrogate biomarkers for clinical trials.
Our biomarker assays not only enable faster drug development but also improve disease outcomes for chronically ill patients by predicting treatment response.
